GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biofrontera BFRI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.89

+7.19%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Biofrontera

From its filings with the US Securities and Exchange Commission

SEC filings

Biofrontera is based in Woburn, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BFRI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $41.7m and a net loss of $10.5m. At that date it held total assets of $28.6m and shareholders' equity of $10.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
14 Oct 2021
Employees
81
Head office
120 PRESIDENTIAL WAY,, WOBURN, MA, 01801
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Prof. Dr. Hermann LuebbertChairman of the Board, Chief Executive Officer, since 2015$1.3m
  • Mr. Eugene Frederick LefflerChief Financial Officer$832,626
  • Mr. George JonesChief Commercial Officer
  • Dr. Heikki LanckrietDirector$55,970
  • Dr. John BorerIndependent Director$91,970
  • Dr. Beth HoffmanIndependent Director$79,970
  • Mr. Kevin WeberIndependent Director$74,970

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Biofrontera Inc is a biopharmaceutical company focused on dermatological treatments.
  • The company has a portfolio of licensed products including Ameluz and Xepi for specific skin conditions.
  • It operates with 81 full-time employees and is headquartered in Woburn, Massachusetts.

Weaknesses

  • The company has a limited product portfolio focused on dermatological conditions.
  • It relies on licensed products rather than developing its own pharmaceuticals.
  • The company went public in 2021, indicating a relatively recent market presence.

Opportunities

  • Expanding the use of Ameluz for additional dermatological conditions could increase market reach.
  • Growing demand for treatments of skin conditions like actinic keratoses and impetigo presents opportunities.
  • Potential for international expansion of its licensed products beyond the United States.

Threats

  • Dependence on a limited number of licensed products poses business risk.
  • Competition in the dermatological pharmaceutical market could impact market share.
  • Regulatory challenges may affect the commercialization of its products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.